Shikiar Asset Management Inc. Has $1.84 Million Stock Position in Danaher Co. (NYSE:DHR)

Shikiar Asset Management Inc. reduced its stake in Danaher Co. (NYSE:DHR) by 3.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,372 shares of the conglomerate’s stock after selling 245 shares during the quarter. Shikiar Asset Management Inc.’s holdings in Danaher were worth $1,842,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Danaher in the fourth quarter valued at approximately $1,752,382,000. Vanguard Group Inc. increased its holdings in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Swedbank AB bought a new stake in shares of Danaher during the first quarter valued at approximately $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Danaher by 214.4% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after acquiring an additional 2,096,038 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on DHR shares. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Jefferies Financial Group began coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Citigroup upped their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price target for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Stock Performance

Shares of NYSE DHR traded down $0.63 during trading on Wednesday, reaching $268.08. 1,321,186 shares of the stock traded hands, compared to its average volume of 2,877,424. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a 50-day moving average of $257.53 and a 200-day moving average of $252.98. The stock has a market capitalization of $198.56 billion, a P/E ratio of 45.54, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. Analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,712 shares of company stock valued at $13,173,269. Corporate insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.